Analysts Offer Insights on Technology Companies: Sensata (ST) and Develop Global Limited (OtherVTEXF)
There's a lot to be optimistic about in the Technology sector as 2 analysts just weighed in on Sensata (ST – Research Report) and Develop Global Limited (VTEXF – Research Report) with bullish sentiments.
Confident Investing Starts Here:
Sensata (ST)
TD Cowen analyst Joseph C Giordano maintained a Buy rating on Sensata yesterday and set a price target of $45.00. The company's shares closed last Monday at $25.70, close to its 52-week low of $24.42.
According to TipRanks.com, Giordano is a 5-star analyst with an average return of 7.7% and a 60.7% success rate. Giordano covers the Industrial Goods sector, focusing on stocks such as Watts Water Technologies, Veralto Corporation, and Rockwell Automation.
Currently, the analyst consensus on Sensata is a Hold with an average price target of $28.30.
Develop Global Limited (VTEXF)
In a report issued on May 29, Tim McCormack from Canaccord Genuity maintained a Buy rating on Develop Global Limited, with a price target of A$5.05. The company's shares closed last Tuesday at $1.40.
According to TipRanks.com, McCormack is a top 100 analyst with an average return of 22.7% and a 66.5% success rate. McCormack covers the Basic Materials sector, focusing on stocks such as Northern Star Resources Ltd, Ramelius Resources Limited, and Gascoyne Resources Limited.
Currently, the analyst consensus on Develop Global Limited is a Moderate Buy with an average price target of $2.92.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
a day ago
- Yahoo
Why Tempus AI Stock Soared 15% Today
Tempus AI was targeted by a short seller last week. Since then, the company has made several announcements that have helped quell doubts introduced by the short report. TD Cowen maintained its buy rating today. 10 stocks we like better than Tempus Ai › Shares of Tempus AI (NASDAQ: TEM) soared on Monday. The company's stock jumped 15% as of market close. The spike comes as the S&P 500 (SNPINDEX: ^GSPC) and the Nasdaq Composite (NASDAQINDEX: ^IXIC) jumped 0.4% and 0.6%, respectively. Tempus, a "precision medicine" company that leverages artificial intelligence (AI) to better treat patients, was the target of a short report last week alleging, among other things, that Tempus is overstating its use of AI. On Friday and Saturday, the company made announcements regarding two AI-driven programs. Whether the timing was deliberate or not, the announcements appeared to help quell doubts introduced by the short seller allegations. Tempus One, the company's AI platform that is intended to help physicians make better decisions, got a key update. The company announced Saturday that the platform will now have direct access to electronic health records (EHR) systems. As the company describes it, the expanded access to data allows the platform to "capture real-time clinical, molecular and imaging data from millions of patients and makes that data easily digestible and useful for clinicians and care teams." On Friday, the company announced an initiative it calls Fuses. The company says it will use its vast amount of clinical data to create "an AI-enabled diagnostic platform offering physicians the largest suite of algorithmic tests designed to make precision medicine a reality." Today, investors were also pleased to see that TD Cowen is maintaining its buy rating, unconvinced by the short seller's allegations. Despite this, and the company's recent announcements, I believe that Tempus' stock is currently overvalued even if the short seller's allegations don't hold up. Before you buy stock in Tempus Ai, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Tempus Ai wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $651,049!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $828,224!* Now, it's worth noting Stock Advisor's total average return is 979% — a market-crushing outperformance compared to 171% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 2, 2025 Johnny Rice has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. Why Tempus AI Stock Soared 15% Today was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Insider
a day ago
- Business Insider
Analysts Offer Insights on Industrial Goods Companies: Performance Shipping (PSHG) and Sterling Construction (STRL)
There's a lot to be optimistic about in the Industrial Goods sector as 2 analysts just weighed in on Performance Shipping (PSHG – Research Report) and Sterling Construction (STRL – Research Report) with bullish sentiments. Confident Investing Starts Here: Performance Shipping (PSHG) In a report issued on May 30, Tate Sullivan from Maxim Group reiterated a Buy rating on Performance Shipping, with a price target of $5.00. The company's shares closed last Tuesday at $1.60, close to its 52-week low of $1.48. According to Sullivan 's ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -9.9% and a 38.7% success rate. Sullivan covers the Industrial Goods sector, focusing on stocks such as United Maritime Corp., Seanergy Maritime, and BWX Technologies. The the analyst consensus on Performance Shipping is currently a Hold rating. William Blair analyst Louie DiPalma maintained a Buy rating on Sterling Construction today. The company's shares closed last Tuesday at $194.23, close to its 52-week high of $206.07. According to DiPalma has 0 stars on 0-5 stars ranking scale with an average return of -11.7% and a 60.6% success rate. DiPalma covers the Technology sector, focusing on stocks such as Palantir Technologies, Science Applications, and BigBearai Holdings. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Sterling Construction with a $205.00 average price target.
Business Insider
a day ago
- Business Insider
Analysts Offer Insights on Healthcare Companies: Exact Sciences (EXAS) and Arcus Biosciences (RCUS)
There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Exact Sciences (EXAS – Research Report) and Arcus Biosciences (RCUS – Research Report) with bullish sentiments. Confident Investing Starts Here: Exact Sciences (EXAS) In a report issued on June 2, Brandon Couillard from Wells Fargo maintained a Buy rating on Exact Sciences, with a price target of $68.00. The company's shares closed last Tuesday at $54.84. According to Couillard is a 5-star analyst with an average return of 14.1% and a 59.5% success rate. Couillard covers the Healthcare sector, focusing on stocks such as Maravai Lifesciences Holdings, Bio-Rad Laboratories, and Myriad Genetics. Exact Sciences has an analyst consensus of Strong Buy, with a price target consensus of $69.94. In a report issued on June 2, Daina Graybosch from Leerink Partners maintained a Buy rating on Arcus Biosciences, with a price target of $46.00. The company's shares closed last Tuesday at $10.03. According to Graybosch has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -15.0% and a 33.3% success rate. Graybosch covers the Healthcare sector, focusing on stocks such as Turnstone Biologics Corp., Werewolf Therapeutics, and Century Therapeutics. Currently, the analyst consensus on Arcus Biosciences is a Strong Buy with an average price target of $27.88, representing a 203.4% upside. In a report issued on May 23, Barclays also maintained a Buy rating on the stock with a $14.00 price target.
